The first Chinese R&D center focusing on translational medicine QIAGEN (Suzhou) Translational Medicine Center has been put into operation as a JV between German QIAGEN and SIP Biotech Development Co., Ltd. (BioBAY).
Translational medicine is a burgeoning scientific realm aiming to accelerate clinical application of research results. Making full use of advanced molecular diagnosis technology from QIAGEN, the center will offer service and consultation to pharmaceutical companies and research institutes home and abroad to speed up the development of translational medicine. Covering four major fields including bio-banking, pharmacogenetics, next generation sequencing (NGS) and pharmacogenomics, the center will form cooperation with BioBAY and other Chinese partners in offering complete biomarker solutions to quicken drug research and development and commercial application of companion diagnostics.
QIAGEN is listed in Netherlands, headquartered in Germany, being a world leading provider of sample and assay technology.
